Zhitong dissolves Hong Kong stocks | Insurance capital invests to establish a stabilization fund to actively enter the market and go long
Today is the last day of November. The Hang Seng Index finally closed the Xiaoyang line. Although it only rose 0.29%, it is significant because the index has returned above 17,000 points, at least shorting forces have been curbed to a certain extent.
Insiders Sold CN¥11m Of Peijia Medical Stock Possibly Sending Warning Sign
Despite a 14% gain in Peijia Medical Limited's (HKG:9996) stock price this week, shareholders shouldn't let up. Although prices were relatively low, insiders chose to sell CN¥11m worth of stock in th
Estimating The Fair Value Of Peijia Medical Limited (HKG:9996)
Key Insights The projected fair value for Peijia Medical is HK$7.38 based on 2 Stage Free Cash Flow to Equity Current share price of HK$7.45 suggests Peijia Medical is potentially trading close to i
Peijia Medical-B (09996.HK): GeminiOne Teer system and MonarqTM TTVR system unveiled at the 2023 US TCT Academic Conference
On October 27, Gelonghui, Peijia Medical-B (09996.HK) announced that the GeminiOne Teer system and MonarqTM TTVR system were unveiled at the 2023 US TCT Academic Conference. Dr. Saibal Kar, M.D., Director of the Cardiology Program at Los Robles Regional Medical Center and Director of Interventional Cardiology at HCA Healthcare, introduced the Geminione TEER system and the early development of this device in the Mitral Valve TEER section
[Brokerage Focus] CITIC Construction Investment Securities gave Peijia Healthcare (09996)'s “buy” rating refers to valvular intervention and neurological intervention two-wheel drive, and performance continues to grow at a high level
Jinwu Financial News | According to the CITIC Construction Investment Securities Report, the 23H1 Peijia Medical-B (09996) heart valve intervention business achieved revenue of 108 million yuan, an increase of 107% over the previous year. The rapid growth in the company's valve intervention business is mainly due to the further increase in hospital coverage of the company's products and the rapid release of second-generation recyclable products. By the end of June 23, the company's TAVR products had added coverage to more than 120 hospitals, covering nearly 410 hospitals, and a sales team of 199 people. 23H1's heart valve intervention business achieved revenue of 108 million yuan, an increase of 107% over the previous year. The company's valve intervention
Is Peijia Medical (HKG:9996) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart m
PEIJIA-B: Interim Report 2023
CITIC Construction Investment: Innovative pharmaceutical companies are still optimistic about segments such as prescription drugs and medical devices on the high-value investment track
The Zhitong Finance App learned that CITIC Construction Investment released a research report stating that last week it focused on reviewing the mid-term business conditions of pharmaceutical companies and innovative pharmaceutical companies.
Peijia Healthcare Announces 2023 Interim Results: Sales Revenue Grew Rapidly, Gross Margin Increased Significantly
On August 31, 2023, Peijia Healthcare Limited (9996.HK) (the “Company”) announced its interim results for the period ended June 30, 2023 (the “Reporting Period”). During the reporting period, the company achieved revenue of 224.9 million yuan (RMB, same below), an increase of 89.3% over the previous year. Revenue growth is mainly due to: (i) accelerated commercialization of transcatheter aortic valve replacement (“TAVR”) products and further expansion of market share, including the first-generation product TaurusOne and the second-generation recyclable product TaurusElite; (ii) ongoing neurological intervention products
PEIJIA-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023
Peijia Medical-B (09996.HK) plans to hold a board meeting on August 31 to approve the interim results
Glonghui, August 18, 丨 Peijia Medical-B (09996.HK) announced that the company will hold a board meeting on August 31, 2023 (Thursday) to consider and approve (among other things) the interim results of the company and its subsidiaries for the six months ended June 30, 2023 and their publication, and to consider recommending the payment of interim dividends (if any).
PEIJIA-B: DATE OF BOARD MEETING
Shareholders in Peijia Medical (HKG:9996) Have Lost 73%, as Stock Drops 6.8% This Past Week
Peijia Medical Limited (HKG:9996) shareholders should be happy to see the share price up 18% in the last month. But that is meagre solace in the face of the shocking decline over three years. Inde
Medical Device Biz Attracts High-end Manufacturers
China's high-end manufacturers are making inroads into the domestic medical device sector, injecting impetus into its high-quality development.
Selected Announcements | Kuaishou expects to turn a sharp loss into a profit in the first half of the year, with net profit not less than 560 million yuan; Yum China's adjusted net profit in Q2 surged 137% year-on-year
Yao Ming Kant announced its results for the first half of the year, with net profit of about 5.313 billion yuan, up 14.6% year on year; Pacific Shipping released interim results, with shareholders' profit of US$85.3 million, a decrease of 82% over the previous year; Agile Group plans to allocate 346 million new shares of existing shares, raising a net of about HK$387 million.
[Brokerage Focus] Huaan Securities maintains Peijia Healthcare's (09996) “buy” rating, indicating that TAVR's market share continues to expand and accelerate sales of Shenjie products
Huaan Securities released a research report indicating that Peijia Medical-B (09996) TAVR products (transcatheter aortic valve replacement products, including the first-generation product TaurusOne and the second-generation recyclable product TaurusElite) accelerated commercialization. The number of implants completed in the first half of the year was more than 1,200 units, an increase of more than 100% over the previous year, which is equivalent to completing the full year of implants in '22 in half a year. Over the past year, provincial and municipal health insurance bureaus have successively included TAVR consumables fees in health insurance, and there have been major improvements on the payment side. The bank expects the annual industry growth rate to be about 50%; the company's overall growth rate exceeds the industry growth rate, and its market share continues to expand
Peijia Medical's H1 Revenue Rises By Up to 94%
Peijia Medical's (HKG:9996) revenue for the six months ended June 30 lies between 220 million yuan and 230 million yuan, up 85.2% to 93.6% from the year-ago figure of 118.8 million yuan, a Friday fili
The revenue of Peijia Medical-B (09996) in the first half of the year increased by about 85.2%-93.6% year-on-year to about 220 million to 230 million yuan
According to the Zhitong Finance App, Peijia Medical-B (09996) announced that the company's revenue for the six months ended June 30, 2023 increased by about 85.2%-93.6% year on year to about RMB 220 million to RMB 230 million.
While Institutions Invested in Peijia Medical Limited (HKG:9996) Benefited From Last Week's 11% Gain, Retail Investors Stood to Gain the Most
Key Insights Peijia Medical's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 8 shareholders own 50% of the compa
Changes in Hong Kong stocks | Peijia Medical-B (09996) rose more than 6% in Guangfa Index, the company's neurological intervention products are expected to expand rapidly, and this year's revenue is expected to grow at a high rate
The Zhitong Finance App learned that Peijia Medical-B (09996) rose more than 6%. As of press release, it rose 5.83% to HK$7.8, with a turnover of HK$8.1971,000. GF Securities recently released a research report stating that Peijia Healthcare's first-generation and second-generation aortic valve products had been commercialized. By the end of '22, a total of 290 second-generation products had been successfully admitted to the hospital; it achieved revenue of 107 million yuan last year (up 156% over the previous year). It is expected that this year will continue to grow rapidly with the industry's in-hospital recovery and active promotion by cooperative companies. In addition, the company has a multi-pipeline layout in the mitral valve/tricuspid valve market, plus promising neurological intervention products